AnaptysBio, Inc. (ANAB)
Health Care ยท Pharmaceutical Preparations
AnaptysBio, Inc. (ANAB) is listed on Nasdaq, where its shares have traded since January 26, 2017. SentiSense covers AnaptysBio, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Daniel Faga is its chief executive officer. The company reports 104 employees, and its corporate website is www.anaptysbio.com.
About AnaptysBio, Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Latest reported results
AnaptysBio, Inc. reported revenue of $27.5 million for Q2 FY2026, up 23.5% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 205 institutions reported holding ANAB, with 30.1 million shares worth $2.0 billion in aggregate. The largest reported holders were Ecor1 Capital, BlackRock and Vanguard. Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter.
More on ANAB
- ANAB sentiment: whether news and social coverage of AnaptysBio, Inc. leans bullish or bearish, and the stories driving it.
- ANAB ownership: all 205 reporting institutions, plus insider and congressional trades.
- ANAB financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for AnaptysBio, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does AnaptysBio, Inc. do?
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.
What sector is ANAB in?
SentiSense classifies AnaptysBio, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ANAB stock trade?
AnaptysBio, Inc. (ANAB) is listed on Nasdaq, where its shares have traded since January 26, 2017.
Who is the CEO of AnaptysBio, Inc.?
Daniel Faga is the chief executive officer of AnaptysBio, Inc..